Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Esperion (ESPR)
NASDAQ:ESPR
Esperion (ESPR) Stock Price & Analysis
1,375 Followers
ESPR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.70 - $3.40
Previous Close$2.43
Volume2.85M
Average Volume (3M)8.41M
Market Cap
$460.39M
Enterprise Value$502.77M
Total Cash (Recent Filing)$226.61M
Total Debt (Recent Filing)$268.99M
Price to Earnings (P/E)―
Beta1.72
Next Earnings
Aug 12, 2024EPS Estimate
-$0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.00
Shares Outstanding189,460,293
10 Day Avg. Volume9,571,047
30 Day Avg. Volume8,410,851
Standard Deviation0.27
R-Squared0.04
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)-0.92
Price to Sales (P/S)12.98
Price to Cash Flow (P/CF)-2.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.19
Enterprise Value/Gross Profit6.88
Enterprise Value/Ebitda-18.90
Forecast
1Y Price Target
$7.51Price Target Upside209.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Esperion News
Bulls Say, Bears Say
Bulls Say
Commercial StrategyThe company is actively engaged in improving its commercial strategy by ramping up sales forces, developing new promotional materials, and initiating partnerships.
Financial StrategyThe new royalty agreement removes a significant and onerous obligation from the balance sheet and should improve cash flows for the company.
Product ExpansionThe expanded indications for NILEMDO and NUSTENDI were approved by the European Commission, expected to drive increased sales with the broader market reach.
Bears Say
CompetitionMerck’s oral PCSK9i and New Amsterdam’s obicetrapib boast greater LDL-C lowering abilities, prompting experts to believe both will be favored if available.
Market PotentialThe primary prevention market is underdeveloped, suggesting limited potential in that segment.
Prescriber SentimentPrescribers have been largely tepid on BA, and with statins still underutilized in primary prevention, there remain concerns uptake may be modest.
---
Ownership Overview
7.20% Insiders
13.87% Mutual Funds
12.20% Other Institutional Investors
66.72% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ESPR FAQ
What was Esperion’s price range in the past 12 months?
Esperion lowest stock price was $0.70 and its highest was $3.40 in the past 12 months.
What is Esperion’s market cap?
Currently, no data Available
When is Esperion’s upcoming earnings report date?
Esperion’s upcoming earnings report date is Aug 12, 2024 which is in 17 days.
How were Esperion’s earnings last quarter?
Esperion released its earnings results on May 07, 2024. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.049 by $0.291.
Is Esperion overvalued?
According to Wall Street analysts Esperion’s price is currently Undervalued.
Does Esperion pay dividends?
Esperion does not currently pay dividends.
What is Esperion’s EPS estimate?
Esperion’s EPS estimate is -$0.16.
How many shares outstanding does Esperion have?
Esperion has 189,460,300 shares outstanding.
What happened to Esperion’s price movement after its last earnings report?
Esperion reported an EPS of $0.34 in its last earnings report, beating expectations of $0.049. Following the earnings report the stock price went up 11.792%.
Which hedge fund is a major shareholder of Esperion?
Among the largest hedge funds holding Esperion’s share is Woodline Partners LP. It holds Esperion’s shares valued at 21M.
---
Esperion Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.51 (209.05% Upside)
$7.51 (209.05% Upside)
Blogger Sentiment
Bullish
ESPR Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 6.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $19.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
68.75%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
48.15%
Trailing 12-Months
Company Description
Esperion
Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
---
ESPR Company Deck
---
ESPR Earnings Call
Q1 2024
0:00 / 0:00
---
ESPR Stock 12 Month Forecast
Average Price Target
$7.51
▲(209.05% Upside)
Technical Analysis
Best Analysts Covering ESPR
1 Year
1 Year Success Rate
10/26 ratings generated profit
1 Year Average Return
+30.37%
reiterated a buy rating 4 months ago
Copying Thomas Shrader's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of +30.37% per trade.
---